GYRE - Gyre Therapeutics Inc
IEX Last Trade
13.385
-0.345 -2.578%
Share volume: 32,987
Last Updated: Fri 30 Aug 2024 07:58:15 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.73
-0.35
-2.51%
Fundamental analysis
36%
Profitability
16%
Dept financing
14%
Liquidity
53%
Performance
57%
Performance
5 Days
7.24%
1 Month
-3.30%
3 Months
32.28%
6 Months
-44.45%
1 Year
63.87%
2 Year
78.16%
Key data
Stock price
$13.38
DAY RANGE
N/A - N/A
52 WEEK RANGE
$4.80 - $30.40
52 WEEK CHANGE
$1.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Nassim Usman
Region: US
Website:
Employees: 35
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 35
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
Recent news